SAFETY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN BIOLOGICAL TREATMENT OVER 65 YEARS OF AGE

被引：0
|
作者：
Crespo Golmar, A.
Moriano, C.
Gonzalez Fernandez, I.
Larco Rojas, X. E.
Lopez Robles, A.
Perez Sandoval, T.
机构：
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.5260
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0622-HP
引用
收藏
页码：1267 / 1267
页数：1
相关论文
共 50 条
  • [31] Acute poisoning in patients over 65 years of age
    Miranda Arto, P.
    Ferrer Dufol, A.
    Ruiz Ruiz, F. J.
    Menao Guillen, S.
    Civeira Murillo, E.
    ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2014, 37 (01) : 99 - 108
  • [32] Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
    Burmester, Gerd R.
    Coates, Laura C.
    Cohen, Stanley B.
    Tanaka, Yoshiya
    Vranic, Ivana
    Nagy, Edward
    Lazariciu, Irina
    Chen, All-shine
    Kwok, Kenneth
    Fallon, Lara
    Kinch, Cassandra
    RHEUMATOLOGY AND THERAPY, 2023, 10 (05) : 1255 - 1276
  • [33] POST-MARKETING SAFETY SURVEILLANCE OF TOFACITINIB OVER 9 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS
    Burmester, G. R.
    Coates, L.
    Cohen, S. B.
    Tanaka, Y.
    Vranic, I.
    Nagy, E.
    Chen, A. S.
    Lazariciu, I.
    Kwok, K.
    Fallon, L.
    Kinch, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 347 - 348
  • [34] Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
    Gerd R. Burmester
    Laura C. Coates
    Stanley B. Cohen
    Yoshiya Tanaka
    Ivana Vranic
    Edward Nagy
    Irina Lazariciu
    All-shine Chen
    Kenneth Kwok
    Lara Fallon
    Cassandra Kinch
    Rheumatology and Therapy, 2023, 10 : 1255 - 1276
  • [35] Safety and Efficacy of the Newer Biological Therapeutics in the Treatment of Rheumatoid Arthritis
    Navarro-Compan, Victoria
    Navarro-Sarabia, Federico
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2011, 3 : 195 - 203
  • [36] Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis
    Lebwohl, M
    Gottlieb, A
    Wallis, W
    Zitnik, R
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P195 - P195
  • [37] Mobilization in patients over 65 years of age and patients between 55 to 65 years of age is similar in terms of safety and success in Multiple Myeloma and lymphoma patients: A Single Center Experience
    Cekdemir, D.
    Atesoglu, E. Birtas
    Bai, C.
    Dora, I.
    Kosan, B.
    Er, E.
    Baskan, N.
    Saritas, B.
    Kural, S.
    Gucyener, E.
    Sengezer, M.
    Tiryaki, N.
    Gulbas, Z.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S130 - S131
  • [38] Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
    Winthrop, Kevin L.
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Kivitz, Alan
    Matzkies, Franziska
    Genovese, Mark C.
    Jiang, Deyuan
    Chen, Kun
    Bartok, Beatrix
    Jahreis, Angelika
    Besuyen, Robin
    Burmester, Gerd R.
    Gottenberg, Jacques-Eric
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (02) : 184 - 192
  • [39] Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
    Burmester, Gerd R.
    Gottenberg, Jacques-Eric
    Caporali, Roberto
    Winthrop, Kevin L.
    Tanaka, Yoshiya
    Omoruyi, Edmund V. Ekoka
    Rajendran, Vijay
    Van Hoek, Paul
    Van Beneden, Katrien
    Takeuchi, Tsutomu
    Westhovens, Rene
    Aletaha, Daniel
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (09) : 1110 - 1117
  • [40] The Safety of Biological Medicines for Rheumatoid Arthritis
    Papadopoulos, Ioannis
    Demetzos, Costas
    Markantoni-Kyroudi, Sofia
    Souliotis, Kyriakos
    GENEDIS 2014: NEURODEGENERATION, 2015, 822 : 209 - 210
12345